(Q27853105)

English

Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib

scientific article

In more languages

Statements

scholarly article

1 reference

PubMed publication ID

13 November 2016

Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib (English)

1 reference

PubMed publication ID

13 November 2016

15

0 references

Marlous Hoogstraat

1

0 references

Marijn van Stralen

object named as

Marijn van Stralen

7

0 references

13

object named as

Daniel S Peeper

0 references

author name string

Christa G Gadellaa-van Hooijdonk

2

0 references

Inge Ubink

3

0 references

Nicolle J M Besselink

4

0 references

Mark Pieterse

5

0 references

Wouter Veldhuis

6

0 references

Eelco F J Meijer

8

0 references

Stefan M Willems

9

0 references

Michael A Hadders

10

0 references

Thomas Kuilman

11

0 references

Oscar Krijgsman

12

0 references

Marco J Koudijs

14

0 references

Emile E Voest

16

0 references

Martijn P Lolkema

17

0 references

publication date

May 2015

0 references

Pigment Cell & Melanoma Research

0 references

28

0 references

3

0 references

318-23

0 references

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

MEK1 mutations confer resistance to MEK and B-RAF inhibition

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Semi-automatic software increases CT measurement accuracy but not response classification of colorectal liver metastases after chemotherapy.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Tumor adaptation and resistance to RAF inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Tumor volume as an alternative response measurement for imatinib treated GIST patients

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Identification of genetic disparity between primary and metastatic melanoma in human patients

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Identifiers

10.1111/PCMR.12347

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

PubMed publication ID

13 November 2016

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853105&oldid=1878795093"